T. Rowe Price Associates’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.29M | Sell |
1,120,631
-52,463
| -4% | -$341K | ﹤0.01% | 1190 |
|
|
2025
Q1 | $9.3M | Sell |
1,173,094
-533,018
| -31% | -$4.23M | ﹤0.01% | 1126 |
|
|
2024
Q4 | $21.6M | Sell |
1,706,112
-838,751
| -33% | -$10.6M | ﹤0.01% | 976 |
|
|
2024
Q3 | $35.5M | Buy |
2,544,863
+193,983
| +8% | +$2.7M | ﹤0.01% | 847 |
|
|
2024
Q2 | $32.4M | Buy |
2,350,880
+51,116
| +2% | +$704K | ﹤0.01% | 839 |
|
|
2024
Q1 | $38M | Sell |
2,299,764
-17,000
| -0.7% | -$281K | ﹤0.01% | 791 |
|
|
2023
Q4 | $33.8M | Buy |
2,316,764
+8,736
| +0.4% | +$128K | ﹤0.01% | 806 |
|
|
2023
Q3 | $28.3M | Sell |
2,308,028
-1,703
| -0.1% | -$20.9K | ﹤0.01% | 830 |
|
|
2023
Q2 | $27.6M | Buy |
2,309,731
+644,980
| +39% | +$7.7M | ﹤0.01% | 847 |
|
|
2023
Q1 | $22.3M | Sell |
1,664,751
-517,827
| -24% | -$6.92M | ﹤0.01% | 895 |
|
|
2022
Q4 | $47M | Buy |
2,182,578
+87,665
| +4% | +$1.89M | 0.01% | 677 |
|
|
2022
Q3 | $42M | Buy |
2,094,913
+53,569
| +3% | +$1.07M | 0.01% | 697 |
|
|
2022
Q2 | $36.5M | Buy |
2,041,344
+455,603
| +29% | +$8.16M | ﹤0.01% | 983 |
|
|
2022
Q1 | $15.7M | Buy |
1,585,741
+4,763
| +0.3% | +$47.3K | ﹤0.01% | 1290 |
|
|
2021
Q4 | $26.6M | Buy |
1,580,978
+74,652
| +5% | +$1.26M | ﹤0.01% | 1208 |
|
|
2021
Q3 | $34.9M | Buy |
1,506,326
+930
| +0.1% | +$21.5K | ﹤0.01% | 1136 |
|
|
2021
Q2 | $33.4M | Buy |
+1,505,396
| New | +$33.4M | ﹤0.01% | 1168 |
|